April 2019

Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception in 2011. She has a research background in CRISPR-Cas biology, and is also a co-founder of Intellia Therapeutics. In 2014, she was named by Forbes Magazine to the "30 Under 30" list in Science and Healthcare, and in 2016, Fortune Magazine named her to the "40 Under 40" list of the most influential young people in business. In 2018, the Association for Women in Science recognized Rachel with the annual Next Generation Award. Rachel is an inventor on several patents and patent applications...Read more

David is a young investigator at the Institut Pasteur in the department of Microbiology where he started his group in 2014. David obtained an engineer degree from AgroParisTech as well as a master degree and PhD from Paris Diderot University for his work performed at the Institut Pasteur on the integron bacterial recombination system. He then joined the laboratory of Luciano Marraffini at the Rockefeller University as a postdoctoral fellow where he started to work on CRISPR-Cas systems. He pioneered the use of CRISPR-Cas systems to edit bacterial genomes, control gene expression and kill...Read more